CN113195469A - 含氮并环化合物、其制备方法及用途 - Google Patents

含氮并环化合物、其制备方法及用途 Download PDF

Info

Publication number
CN113195469A
CN113195469A CN202080007098.7A CN202080007098A CN113195469A CN 113195469 A CN113195469 A CN 113195469A CN 202080007098 A CN202080007098 A CN 202080007098A CN 113195469 A CN113195469 A CN 113195469A
Authority
CN
China
Prior art keywords
membered
compound
radical
cycloalkyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080007098.7A
Other languages
English (en)
Inventor
李桂英
游泽金
何云
田强
宋宏梅
薛彤彤
王晶翼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Publication of CN113195469A publication Critical patent/CN113195469A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

本发明涉及含氮并环化合物、其制备方法及用途。具体而言，本发明涉及具有式X所示结构的化合物，所述化合物的立体异构体、互变异构体或其混合物，所述化合物的药学上可接受的盐、共晶、多晶型物或溶剂合物，或者所述化合物的稳定同位素衍生物、代谢物或前药。本发明的化合物可以具有式I或式II所示结构。这些化合物可用于细胞增殖异常性疾病(例如癌症)的治疗。

Description

PCT国内申请，说明书已公开。

Claims (19)

  1. PCT国内申请，权利要求书已公开。
CN202080007098.7A 2019-02-19 2020-02-10 含氮并环化合物、其制备方法及用途 Pending CN113195469A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2019101240486 2019-02-19
CN201910124048 2019-02-19
CN2019104889690 2019-06-06
CN201910488969 2019-06-06
CN2019109321566 2019-09-29
CN201910932156 2019-09-29
PCT/CN2020/074572 WO2020168927A1 (zh) 2019-02-19 2020-02-10 含氮并环化合物、其制备方法及用途

Publications (1)

Publication Number Publication Date
CN113195469A true CN113195469A (zh) 2021-07-30

Family

ID=72144770

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080007098.7A Pending CN113195469A (zh) 2019-02-19 2020-02-10 含氮并环化合物、其制备方法及用途

Country Status (4)

Country Link
US (1) US20220056043A1 (zh)
EP (1) EP3929185A4 (zh)
CN (1) CN113195469A (zh)
WO (1) WO2020168927A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114235976A (zh) * 2021-11-09 2022-03-25 暨南大学 一种含氮杂环有机化合物中间产物的合成和分析方法
CN114269753A (zh) * 2019-09-29 2022-04-01 四川科伦博泰生物医药股份有限公司 一种含氮并环类化合物，包含其的药物组合物，其制备方法及其用途
CN115716840A (zh) * 2021-08-24 2023-02-28 昆药集团股份有限公司 一种具有kras突变蛋白抑制作用的杂环化合物及其药物组合和用途
CN116832026B (zh) * 2023-05-25 2024-03-29 新乡医学院 Nlrp3基因敲除和/或nlrp3抑制剂mcc950在预防和/或治疗***的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023250316A1 (en) * 2022-06-22 2023-12-28 Ptc Therapeutics, Inc. Compounds for treating spinocerebellar ataxia type 3

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1714092A (zh) * 2002-11-25 2005-12-28 惠氏公司 作为蛋白激酶抑制剂的噻吩并[3,2－b]吡啶－6－腈和噻吩并[2,3－b]吡啶－5－腈
EP1724268A1 (en) * 2004-02-20 2006-11-22 Kirin Beer Kabushiki Kaisha Compound having tgf-beta inhibitory activity and pharmaceutical composition containing same
CN101328186A (zh) * 1997-11-11 2008-12-24 辉瑞产品公司 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物
CN103492377A (zh) * 2011-02-25 2014-01-01 阵列生物制药公司 作为pim激酶抑制剂的***并吡啶化合物
US20160102080A1 (en) * 2014-10-09 2016-04-14 Allergan, Inc. Pyridyl benzothiophenes as kinase inhibitors
AR104777A1 (es) * 2015-04-03 2017-08-16 Incyte Corp Derivados de 4-(imidazo[1,2-c]pirimidina-7-il)-benzonitrilo como inhibidores de lsd1
WO2017184735A1 (en) * 2016-04-19 2017-10-26 Ifm Therapeutics, Inc Nlrp3 modulators
US20180186745A1 (en) * 2016-12-22 2018-07-05 Global Blood Therapeutics, Inc. Histone methyltransferase inhibitors
CN108699067A (zh) * 2016-11-11 2018-10-23 上海海雁医药科技有限公司 吡啶胺取代的杂三环化合物、其制法与医药上的用途
CN109071535A (zh) * 2016-04-19 2018-12-21 先天肿瘤免疫公司 Nlrp3调节剂
WO2019014402A1 (en) * 2017-07-14 2019-01-17 Innate Tumor Immunity, Inc. MODULATORS OF NLRP3

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2285263C (en) * 1997-04-11 2009-03-10 Abbott Laboratories Furopyridine, thienopyridine, pyrrolopyridine and related pyrimidine, pyridazine and triazine compounds useful in controlling chemical synaptic transmission
UA77303C2 (en) * 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
TW200510373A (en) * 2003-07-14 2005-03-16 Neurogen Corp Substituted quinolin-4-ylamine analogues
BRPI0819328A8 (pt) * 2007-11-15 2016-02-10 Boehringer Ingelheim Int Compostos inibidores de replicação de vírus da imunodeficiência humana, composição farmacêutica e uso dos ditos compostos
JP6218848B2 (ja) * 2012-11-20 2017-10-25 プロキナーゼ ゲゼルシャフト ミット ベシュレンクテル ハフツング プロテインキナーゼ阻害剤としてのチオエーテル誘導体
KR101602559B1 (ko) * 2014-04-29 2016-03-10 경북대학교 산학협력단 2,5,6,7-사중치환 티아졸로[4,5-b]피리딘 유도체 및 이의 용도
WO2016022644A1 (en) * 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
CN105820175B (zh) * 2016-04-13 2019-09-20 四川大学 一种噻吩并嘧啶类化合物及其制备方法和应用
EP3851434A1 (en) * 2017-01-23 2021-07-21 Genentech, Inc. Chemical compounds as inhibitors of interleukin-1 activity
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
SG11201911929XA (en) * 2017-06-21 2020-01-30 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CN111303070B (zh) * 2017-06-26 2024-02-23 中国科学技术大学 噻唑啉酮杂环化合物、其制备方法以及药用组合物
CN108586486B (zh) * 2018-06-19 2021-03-02 四川大学 一种芳基取代噻吩并嘧啶类化合物的制备方法

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101328186A (zh) * 1997-11-11 2008-12-24 辉瑞产品公司 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物
CN1714092A (zh) * 2002-11-25 2005-12-28 惠氏公司 作为蛋白激酶抑制剂的噻吩并[3,2－b]吡啶－6－腈和噻吩并[2,3－b]吡啶－5－腈
EP1724268A1 (en) * 2004-02-20 2006-11-22 Kirin Beer Kabushiki Kaisha Compound having tgf-beta inhibitory activity and pharmaceutical composition containing same
CN103492377A (zh) * 2011-02-25 2014-01-01 阵列生物制药公司 作为pim激酶抑制剂的***并吡啶化合物
US20160102080A1 (en) * 2014-10-09 2016-04-14 Allergan, Inc. Pyridyl benzothiophenes as kinase inhibitors
AR104777A1 (es) * 2015-04-03 2017-08-16 Incyte Corp Derivados de 4-(imidazo[1,2-c]pirimidina-7-il)-benzonitrilo como inhibidores de lsd1
WO2017184735A1 (en) * 2016-04-19 2017-10-26 Ifm Therapeutics, Inc Nlrp3 modulators
CN109071535A (zh) * 2016-04-19 2018-12-21 先天肿瘤免疫公司 Nlrp3调节剂
CN108699067A (zh) * 2016-11-11 2018-10-23 上海海雁医药科技有限公司 吡啶胺取代的杂三环化合物、其制法与医药上的用途
US20180186745A1 (en) * 2016-12-22 2018-07-05 Global Blood Therapeutics, Inc. Histone methyltransferase inhibitors
WO2019014402A1 (en) * 2017-07-14 2019-01-17 Innate Tumor Immunity, Inc. MODULATORS OF NLRP3

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GONZALEZ CABRERA, DIEGO ET AL.: "Structure-Activity Relationship Studies of Orally Active Antimalarial 2,4-Diamino-thienopyrimidines", 《JOURNAL OF MEDICINAL CHEMISTRY》, vol. 58, no. 18, pages 7572 - 7579, XP055488177, DOI: 10.1021/acs.jmedchem.5b01156 *
JIALING CAI ET AL.: "Access to functionalized thienopyridines via a reagent-capsule-assisted coupling, thiolation and cyclization cascade sequence", 《ORG. BIOMOL. CHEM.》, vol. 15, pages 333 - 337, XP055729169, DOI: 10.1039/C6OB02351G *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114269753A (zh) * 2019-09-29 2022-04-01 四川科伦博泰生物医药股份有限公司 一种含氮并环类化合物，包含其的药物组合物，其制备方法及其用途
CN114269753B (zh) * 2019-09-29 2024-03-05 四川科伦博泰生物医药股份有限公司 一种含氮并环类化合物，包含其的药物组合物，其制备方法及其用途
CN115716840A (zh) * 2021-08-24 2023-02-28 昆药集团股份有限公司 一种具有kras突变蛋白抑制作用的杂环化合物及其药物组合和用途
CN114235976A (zh) * 2021-11-09 2022-03-25 暨南大学 一种含氮杂环有机化合物中间产物的合成和分析方法
CN114235976B (zh) * 2021-11-09 2023-11-03 暨南大学 一种含氮杂环有机化合物中间产物的合成和分析方法
CN116832026B (zh) * 2023-05-25 2024-03-29 新乡医学院 Nlrp3基因敲除和/或nlrp3抑制剂mcc950在预防和/或治疗***的应用

Also Published As

Publication number Publication date
EP3929185A4 (en) 2023-02-15
US20220056043A1 (en) 2022-02-24
WO2020168927A1 (zh) 2020-08-27
EP3929185A1 (en) 2021-12-29

Similar Documents

Publication Publication Date Title
CN113195469A (zh) 含氮并环化合物、其制备方法及用途
ES2857251T3 (es) Compuestos polifluorados que actúan como inhibidores de la tirosina cinasa de bruton
CN113454083A (zh) Kras突变蛋白抑制剂
KR101982912B1 (ko) 융합된 헤테로사이클릭 화합물, 이의 제조 방법, 약학적 조성물, 및 그 용도
US11787803B2 (en) Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors
CN113637005A (zh) 用于癌症治疗的kras抑制剂
CN110156786A (zh) 嘧啶并环化合物及其制备方法和应用
WO2014113191A1 (en) Hedgehog pathway signaling inhibitors and therapeutic applications thereof
KR101947289B1 (ko) 신규 피롤로피리미딘 화합물 또는 그의 염, 및 이것을 함유하는 의약 조성물, 특히 nae 저해 작용에 기초하는 종양 등의 예방제 및/또는 치료제
KR20220028072A (ko) Bet 억제제로서의 헤테로시클릭 화합물
JP2021525252A (ja) 三環式誘導体を含む阻害剤、その製造方法、及び使用
CN114728926A (zh) 一种rock抑制剂及其制备方法和用途
CN111386275A (zh) 高活性sting蛋白激动剂
CN112654622B (zh) 并环化合物、其制备方法及用途
US20220259210A1 (en) Pyrazolone-Fused Pyrimidine Compound, Preparation Method for Same and Applications Thereof
CN114555565B (zh) 含氮并环化合物、其制备方法及用途
CN115403584A (zh) 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用
CN114667286A (zh) 用于治疗自身免疫性疾病的三氮杂三环类化合物
CN114269753B (zh) 一种含氮并环类化合物，包含其的药物组合物，其制备方法及其用途
CN110724076B (zh) 对芳基二甲酰胺类化合物、包含其的药物组合物、其制备方法及其用途
EP4219453A1 (en) Pyrazole compound and preparation method therefor and use thereof
WO2023220247A1 (en) Lrrk2 inhibitors
CN111825694A (zh) 稠环化合物、其制备方法及用途
CN117164583A (zh) 一种靶向irak4蛋白降解的化合物及其应用
CN111253390A (zh) 并环化合物、其制备方法及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination